Kidney Cancer FAQ
Kidney Cancer FAQ
The questions below are the practical ones — what treatment costs, how long you stay, which medicines are available, how records travel, and what happens once you are home. Conceptual questions about the disease itself are answered on the overview page .
What treatment costs
The figures most patients look for are comparative rather than absolute, and the reliable statement we can make is this: treatment in China typically costs 30% to 50% of the equivalent treatment in Europe or the United States. A formal quotation is prepared from your own records rather than from a published price list.
- The operation — partial nephrectomy, radical nephrectomy, or a more complex procedure where the tumour extends into the vein.
- Hospital days — a partial nephrectomy is a shorter admission than a radical nephrectomy; ablation is shorter still.
- Imaging and pathology — the multiphasic scan, any biopsy, and the full pathology reporting including the subtype and grade.
- Medicines — if systemic treatment is needed, the drugs differ substantially in price, and immunotherapy combinations sit at the upper end.
- Follow-up — surveillance imaging, blood tests and any treatment given after surgery.
Because the same cancer can be dealt with in one short admission or by long-term medication, totals differ enormously between patients, and a quotation only means something once the plan is settled. The range above is a range across our network, not a quote for your case; travel, accommodation and the length of the stay are real costs that sit alongside the hospital bill.
How long you need to stay
Duration depends on which treatment the findings support and on the recovery that treatment requires:
- Partial nephrectomy — usually a few days in hospital, with a return to normal activity over a few weeks. Laparoscopic and robot-assisted approaches typically shorten the recovery.
- Radical nephrectomy — a hospital stay measured in days, followed by several weeks before long-haul travel is comfortable and appropriate.
- Ablation — usually a short admission, often one or two nights, with a return to normal activity more quickly than after an operation.
- Complex surgery involving the vein — a longer admission and a longer recovery, and it should be planned with more generous margins for the return journey.
- Systemic treatment — given in cycles rather than as a single stay, so the time in hospital alternates with periods at home; this is the route that most changes how a stay is scheduled.
Two practical instructions follow. Do not book the return flight against the discharge date — fitness to fly after abdominal surgery is assessed separately and the interval varies between individuals. And if what you need first is an assessment rather than treatment, that can usually be done from your records before travelling, which avoids a journey made only to confirm a plan that could have been drawn up remotely.
Which medicines are available
Patients often ask whether the specific drug they have read about is available here. Two families of medicine are used in kidney cancer, and the agents within them are available in our network:
- Immune checkpoint inhibitors — used in combination with each other or with a targeted agent as first-line treatment for advanced clear cell tumours, and as treatment after surgery for high-risk disease.
- Targeted agents acting on the tumour’s blood supply — the drugs that block the vascular endothelial growth factor pathway, used as single agents and as combination partners.
- mTOR inhibitors — used in combination with a targeted agent after earlier treatment has stopped working.
- Belzutifan — a HIF-2α inhibitor used for kidney tumours in von Hippel-Lindau disease and for previously treated advanced clear cell tumours.
Whether a particular drug suits you depends on the histological subtype, the IMDC risk group, which treatments have already been given, and sometimes on whether a specific genetic change is present — which is why a papillary tumour and a clear cell tumour at the same stage can be treated with entirely different regimens. The availability of a specific drug should be confirmed in writing as part of the plan rather than assumed, and the written assessment is where that confirmation is made.
Sending records and getting a written answer
An assessment can be made before you travel, and the quality of the answer depends on what is sent. For kidney cancer, six items make the difference:
- The multiphasic CT or MRI, as images rather than only as a report — because tumour size, position, and how far a venous thrombus extends are answered by looking, not by reading a summary.
- The pathology report — with the histological subtype and the WHO/ISUP grade, whether from a biopsy or from a previous operation.
- Recent blood tests including creatinine — from which the estimated filtration rate is calculated, since this determines how much kidney can be removed safely.
- A chest scan — for staging, since the lungs are a common site of spread.
- The treatment record so far — which drugs have been given, for how long, and how the disease responded.
- The family history — particularly kidney cancer in a close relative, tumours in both kidneys, or any known inherited condition.
Material in English can be assessed directly, and material in other languages is translated by our team. Where something is missing — most often the original images, or the creatinine result — we say so explicitly, because those are the gaps that stop a treatment route being offered with confidence. The written assessment is issued within 48 hours of the file being complete.
Insurance and payment
Kidney cancer treatment usually involves one substantial episode of care and then a period of surveillance, and both should be considered when you plan how to pay:
- Direct billing — our network has arrangements with more than 55 insurers, allowing eligible patients to be treated without settling the full amount in advance.
- Confirmation before travel — a pre-authorisation is best obtained before arrival, because a procedure arranged at short notice is difficult to authorise retrospectively.
- Coverage of the operation — surgical treatment is usually covered, and the distinction between a partial and a radical nephrectomy is relevant to the estimate rather than to eligibility.
- Coverage of systemic drugs — policies vary more here than for surgery, so whether immunotherapy and targeted agents are covered should be checked early and in writing.
- Self-payment — a formal quotation and an itemised estimate are provided on request.
Two things are worth confirming with the insurer from the outset: whether the policy covers treatment outside your country of residence, and whether it covers medication given over time rather than a single operation. The international patient team can produce the documents an insurer requires, and the earlier this process begins, the less likely it is to delay treatment.
After treatment, and back home
The period after treatment is where planning pays off, because surveillance for kidney cancer continues for years and because kidney function needs to be watched for the long term. What should be arranged before you leave:
- A written surveillance schedule — which scans, at what intervals, for how many years, and whether the chest is included each time.
- The pathology report — with the subtype and grade, since these determine the interval.
- Imaging on disc — so that a clinician at home can compare future scans against the baseline rather than starting from scratch.
- Instructions on what to watch for — blood in the urine, persistent flank pain, new bone pain, unexplained weight loss, and fever.
- A named contact — for questions between visits, including arrangements for a video review.
Two things are worth asking for explicitly. First, the creatinine result and filtration rate measured after treatment, because they become the new baseline for judging kidney function from then on. Second, an arrangement setting out who does what: which scans are done locally with the results sent back here for review, and which are done here. Settling that before the first journey home is what stops the surveillance schedule quietly falling apart.
Eating and daily life during treatment
There is no diet that treats kidney cancer, and any suggestion otherwise should be treated with caution. What nutrition advice can legitimately do is support you through treatment and protect kidney function:
- Protein intake — adequate rather than excessive, particularly if kidney function is reduced; a dietitian review is part of the plan after a nephrectomy rather than an optional extra.
- Salt — moderating salt intake supports blood pressure control, which matters both for kidney protection and because some systemic treatments raise blood pressure.
- Fluids — ordinary adequate hydration; very high fluid intakes are not therapeutic and can be harmful if the kidneys are impaired.
- During immunotherapy or targeted treatment — maintaining weight and managing diarrhoea, fatigue or taste changes matters more than any specific food, and these symptoms should be reported rather than endured.
- Supplements and herbal products — check with the team first, because several interact with treatment or place extra demand on the kidneys.
One specific caution belongs here. If only one kidney remains, anything that stresses the remaining organ — repeated courses of kidney-damaging painkillers, dehydration during illness, or unregulated supplements marketed for kidney health — deserves more scrutiny than it would otherwise. If weight loss or difficulty eating becomes a problem, say so early: nutritional support has a real effect on how well people tolerate treatment.